Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review - H1 2014





Published: March 2014 | Pages: 179 | Format: PDF

 Summary 

 Global Markets Direct’s, ‘Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2014’, provides an overview of the Keratoconjunctivitis sicca (Dry Eye)’s therapeutic pipeline. 

 This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects. 

 Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. 

 The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. 

 Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. 

 Scope 

  •  The report provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye) 
  •  The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities  
  •  The report reviews key players involved in the therapeutics development for Keratoconjunctivitis sicca (Dry Eye) and enlists all their major and minor projects 
  •  The report summarizes all the dormant and discontinued pipeline projects  
  •  A review of the Keratoconjunctivitis sicca (Dry Eye) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
  •  Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
  •  A detailed assessment of monotherapy and combination therapy pipeline projects 
  •  Coverage of the Keratoconjunctivitis sicca (Dry Eye) pipeline on the basis of target, MoA, route of administration and molecule type 
  •  Latest news and deals relating related to pipeline products 

 Reasons to buy 

  •  Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies 
  •  Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
  •  Develop strategic initiatives by understanding the focus areas of leading companies 
  •  Identify and understand important and diverse types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye) 
  •  Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline 
  •  Devise corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) pipeline depth and focus of Indication therapeutics 
  •  Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
  •  Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline 

 

 Table of Contents 

 Introduction 8 

 Global Markets Direct Report Coverage 8 

 Keratoconjunctivitis sicca (Dry Eye) Overview 9 

 Therapeutics Development 10 

 Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) - Overview 10 

 Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis 11 

 Keratoconjunctivitis sicca (Dry Eye) - Therapeutics under Development by Companies 12 

 Keratoconjunctivitis sicca (Dry Eye) - Therapeutics under Investigation by Universities/Institutes 16 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline Products Glance 17 

 Late Stage Products 17 

 Clinical Stage Products 18 

 Early Stage Products 19 

 Unknown Stage Products 20 

 Keratoconjunctivitis sicca (Dry Eye) - Products under Development by Companies 21 

 Keratoconjunctivitis sicca (Dry Eye) - Products under Investigation by Universities/Institutes 23 

 Keratoconjunctivitis sicca (Dry Eye) - Companies Involved in Therapeutics Development 24 

 Alcon, Inc. 24 

 Allergan, Inc. 25 

 Seikagaku Corporation 26 

 Merck & Co., Inc. 27 

 Santen Pharmaceutical Co., Ltd. 28 

 EyeGate Pharmaceuticals, Inc. 29 

 Kissei Pharmaceutical Co., Ltd. 30 

 Rigel Pharmaceuticals, Inc. 31 

 Shire Plc 32 

 Bayer AG 33 

 InSite Vision Incorporated 34 

 NovaBay Pharmaceuticals, Inc. 35 

 Circadian Technologies Limited 36 

 RegeneRx Biopharmaceuticals, Inc. 37 

 HanAll Biopharma Co., Ltd. 38 

 R-Tech Ueno, Ltd. 39 

 Digna Biotech, S.L. 40 

 Scynexis, Inc. 41 

 Lipicard Technologies Limited 42 

 Senju Pharmaceutical Co., Ltd. 43 

 Parion Sciences, Inc. 44 

 Novaliq GmbH 45 

 Kainos Medicine, Inc. 46 

 PharmaNova Inc. 47 

 Resolvyx Pharmaceuticals, Inc 48 

 SIFI S.p.A 49 

 Celsus Therapeutics Plc 50 

 Dompe Farmaceutici S.p.A. 51 

 Mimetogen Pharmaceuticals Inc. 52 

 Kala Pharmaceuticals, Inc. 53 

 Laboratorios Sophia S.A. de C.V. 54 

 Eleven Biotherapeutics 55 

 Laurantis Pharma Oy 56 

 Neuroptis Biotech 57 

 Dong-A Socio Holdings Co Ltd 58 

 Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Assessment 59 

 Assessment by Monotherapy Products 59 

 Assessment by Target 60 

 Assessment by Mechanism of Action 63 

 Assessment by Route of Administration 66 

 Assessment by Molecule Type 68 

 Drug Profiles 70 

 diquafosol tetrasodium - Drug Profile 70 

 cyclosporine - Drug Profile 72 

 lifitegrast - Drug Profile 75 

 dexamethasone acetate - Drug Profile 77 

 MIMD-3 - Drug Profile 79 

 PRO-148 - Drug Profile 80 

 EBI-005 - Drug Profile 82 

 MB-11316 - Drug Profile 83 

 R-348 - Drug Profile 84 

 secukinumab - Drug Profile 86 

 cyclosporine - Drug Profile 89 

 RGN-259 - Drug Profile 90 

 cyclosporine - Drug Profile 92 

 mapracorat - Drug Profile 95 

 ESBA-105 - Drug Profile 97 

 RU-101 - Drug Profile 99 

 recoflavone - Drug Profile 100 

 difluprednate - Drug Profile 102 

 ISV-101 - Drug Profile 103 

 ozagrel - Drug Profile 104 

 SI-614 - Drug Profile 105 

 Recombinant Human Nerve Growth Factor - Drug Profile 106 

 ProtoCure Emulsion Cream - Drug Profile 107 

 Autologous Serum Eyedrops - Drug Profile 110 

 cyclosporine Microemulsion - Drug Profile 111 

 P-17 - Drug Profile 112 

 disitertide - Drug Profile 113 

 P-321 - Drug Profile 115 

 RX-20001 - Drug Profile 116 

 SF-104 - Drug Profile 117 

 VGX-100 - Drug Profile 118 

 HL-036 - Drug Profile 120 

 KeraKlear - Drug Profile 121 

 OPX-1 - Drug Profile 122 

 SCY-641 - Drug Profile 123 

 NVC-727 - Drug Profile 124 

 NVC-638 - Drug Profile 125 

 NVC-704 - Drug Profile 126 

 NOP-3 - Drug Profile 127 

 NOP-5 - Drug Profile 128 

 PN-202 - Drug Profile 129 

 loteprednol etabonate - Drug Profile 130 

 Lacritin - Drug Profile 131 

 KM-401 - Drug Profile 132 

 voclosporin - Drug Profile 133 

 RGN-259 - Drug Profile 136 

 Mucin Secretagogues - Drug Profile 138 

 Keratoconjunctivitis sicca (Dry Eye) - Recent Pipeline Updates 139 

 Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects 166 

 Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products 167 

 Keratoconjunctivitis sicca (Dry Eye) - Product Development Milestones 168 

 Featured News & Press Releases 168 

 Appendix 175 

 Methodology 175 

 Coverage 175 

 Secondary Research 175 

 Primary Research 175 

 Expert Panel Validation 175 

 Contact Us 176 

 Disclaimer 176 

  

 List of Tables 

 Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H1 2014 13 

 Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis, H1 2014 14 

 Number of Products under Development by Companies, H1 2014 16 

 Number of Products under Development by Companies, H1 2014 (Contd..1) 17 

 Number of Products under Development by Companies, H1 2014 (Contd..2) 18 

 Number of Products under Investigation by Universities/Institutes, H1 2014 19 

 Comparative Analysis by Late Stage Development, H1 2014 20 

 Comparative Analysis by Clinical Stage Development, H1 2014 21 

 Comparative Analysis by Early Stage Development, H1 2014 22 

 Comparative Analysis by Unknown Stage Development, H1 2014 23 

 Products under Development by Companies, H1 2014 24 

 Products under Development by Companies, H1 2014 (Contd..1) 25 

 Products under Investigation by Universities/Institutes, H1 2014 26 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Alcon, Inc., H1 2014 27 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Allergan, Inc., H1 2014 28 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Seikagaku Corporation, H1 2014 29 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Merck & Co., Inc., H1 2014 30 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2014 31 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by EyeGate Pharmaceuticals, Inc., H1 2014 32 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2014 33 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Rigel Pharmaceuticals, Inc., H1 2014 34 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Shire Plc, H1 2014 35 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Bayer AG, H1 2014 36 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by InSite Vision Incorporated, H1 2014 37 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by NovaBay Pharmaceuticals, Inc., H1 2014 38 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Circadian Technologies Limited, H1 2014 39 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2014 40 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by HanAll Biopharma Co., Ltd., H1 2014 41 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by R-Tech Ueno, Ltd., H1 2014 42 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Digna Biotech, S.L., H1 2014 43 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Scynexis, Inc., H1 2014 44 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lipicard Technologies Limited, H1 2014 45 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Senju Pharmaceutical Co., Ltd., H1 2014 46 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Parion Sciences, Inc., H1 2014 47 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Novaliq GmbH, H1 2014 48 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kainos Medicine, Inc., H1 2014 49 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by PharmaNova Inc., H1 2014 50 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Resolvyx Pharmaceuticals, Inc, H1 2014 51 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by SIFI S.p.A, H1 2014 52 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Celsus Therapeutics Plc, H1 2014 53 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Dompe Farmaceutici S.p.A., H1 2014 54 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mimetogen Pharmaceuticals Inc., H1 2014 55 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kala Pharmaceuticals, Inc., H1 2014 56 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Laboratorios Sophia S.A. de C.V., H1 2014 57 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Eleven Biotherapeutics, H1 2014 58 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Laurantis Pharma Oy, H1 2014 59 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Neuroptis Biotech, H1 2014 60 

 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2014 61 

 Assessment by Monotherapy Products, H1 2014 62 

 Number of Products by Stage and Target, H1 2014 65 

 Number of Products by Stage and Mechanism of Action, H1 2014 68 

 Number of Products by Stage and Route of Administration, H1 2014 70 

 Number of Products by Stage and Molecule Type, H1 2014 72 

 Keratoconjunctivitis sicca (Dry Eye) Therapeutics - Recent Pipeline Updates, H1 2014 142 

 Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H1 2014 169 

 Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products, H1 2014 170 

  

 List of Figures 

 Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H1 2014 13 

 Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis, H1 2014 14 

 Number of Products under Development by Companies, H1 2014 15 

 Comparative Analysis by Late Stage Development, H1 2014 20 

 Comparative Analysis by Clinical Stage Development, H1 2014 21 

 Comparative Analysis by Early Stage Products, H1 2014 22 

 Assessment by Monotherapy Products, H1 2014 62 

 Number of Products by Top 10 Target, H1 2014 63 

 Number of Products by Stage and Top 10 Target, H1 2014 64 

 Number of Products by Top 10 Mechanism of Action, H1 2014 66 

 Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 67 

 Number of Products by Top 10 Route of Administration, H1 2014 69 

 Number of Products by Stage and Top 10 Route of Administration, H1 2014 70 

 Number of Products by Top 10 Molecule Type, H1 2014 71 

 Number of Products by Stage and Top 10 Molecule Type, H1 2014 72